Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
On July 23, 2025, Dr. Reddy’s Laboratories announced its intention to appoint Deloitte Haskins & Sells LLP as its Statutory Auditors for five years starting from FY 2026-27. This decision, pending regulatory approval, marks a strategic move as the company transitions from its current auditors, M/s. S.R. Batliboi & Associates LLP, whose term concludes at the 42nd AGM in 2026. The appointment reflects Dr. Reddy’s commitment to maintaining high standards of audit independence and compliance, potentially impacting its operational transparency and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The overall stock score for Dr Reddy’s Laboratories is solid, driven primarily by strong financial performance, indicating robust growth and stable operations. However, technical analysis suggests bearish momentum, and the valuation indicates limited dividend income potential, which slightly dampens the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company is committed to providing access to affordable and innovative medicines, offering a portfolio that includes APIs, generics, branded generics, biosimilars, and OTC products. Its major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology, with significant markets in the USA, India, Russia & CIS countries, China, Brazil, and Europe.
Average Trading Volume: 1,584,368
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.99B
Learn more about RDY stock on TipRanks’ Stock Analysis page.